Collectively, these findings suggested that inhibition of the CBP/β-catenin signaling axis by PRI-724 may suppress the invasive capacity of melanoma cells, with the most pronounced effect observed in trametinib-resistant cells. The gene discussed is CREBBP; the disease is melanoma.